This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia (SWN-K)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00749970
First received: September 9, 2008
Last updated: December 8, 2010
Last verified: December 2010
  Purpose
Observational, short-term prospective, multicenter study to assess psychometric properties of the Spanish version of SWN-K scale in patients with schizophrenia.

Condition
Schizophrenia Schizoaffective Disorder Schizophreniform Disorder

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • SWN-K [ Time Frame: 7 days ]
  • PANSS [ Time Frame: 7 days ]

Secondary Outcome Measures:
  • CGI-I [ Time Frame: 7 days ]

Estimated Enrollment: 100
Study Start Date: July 2008
Study Completion Date: January 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patient aged 18-year old or older with a diagnosis of schizophrenia, schizoaffective disorder, or shizophreniform disorder
Criteria

Inclusion Criteria:

  • Patients with a diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder (DSM-IV TR criteria)
  • Stabilized out-patients
  • Under treatment with an oral antipsychotic drug

Exclusion Criteria:

  • Administration of a depot antipsychotic drug
  • Participation in another clinical trial within 4 weeks prior to enrolment into this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00749970

Locations
Spain
Research Site
Alicante, Spain
Research site
Barcelona, Spain
Research site
Burgos, Spain
Research Site
Cordoba, Spain
Research Site
Granada, Spain
Research site
Madrid, Spain
Research Site
Mallorca, Spain
Research Site
Salamanca, Spain
Research Site
Sevilla, Spain
Research site
Tarragona, Spain
Research Site
Valencia, Spain
Research Site
Valladolid, Spain
Research Site
Vitoria, Spain
Research Site
Zaragoza, Spain
Sponsors and Collaborators
AstraZeneca
  More Information

Responsible Party: Teresa Diez, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00749970     History of Changes
Other Study ID Numbers: NIS-NES-DUM-2008/1
Study First Received: September 9, 2008
Last Updated: December 8, 2010

Keywords provided by AstraZeneca:
schizophrenia
subjective well-being
psychometric validation

Additional relevant MeSH terms:
Disease
Schizophrenia
Psychotic Disorders
Pathologic Processes
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs

ClinicalTrials.gov processed this record on June 28, 2017